Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001

Australian and New Zealand Journal of Psychiatry

Volumn 40, Issue 11-12, 2006, Pages 981-986

  Hollis, Jean ^a   Touyz, Stephen ^a   Grayson, David ^a   Forrester, Loelle ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b New South Wales State Office   (Australia)

Author keywords

Antipsychotic; Elderly; Mortality

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROIC ACID;

AGED; AGING; ARTICLE; DRUG FATALITY; DRUG SAFETY; DRUG USE; FEMALE; GENDER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRESCRIPTION; VETERAN; WIDOW;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; AUSTRALIAN CAPITAL TERRITORY; BENZODIAZEPINES; CAUSE OF DEATH; CHLORPROMAZINE; FEMALE; HALOPERIDOL; HUMANS; MALE; NEW SOUTH WALES; ODDS RATIO; PHENOTHIAZINES; POLYPHARMACY; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; RISPERIDONE; THIORIDAZINE; VETERANS; WIDOWHOOD;

EID: 33750034907     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2006.01920.x     Document Type: Article

References (27)

1. Hartikainen S, Rahkonen T, Kautiainen H, Sulkava R. Use of psychotropics among home-dwelling nondemented and demented elderly. International Journal of Geriatric Psychiatry 2003; 18: 1135-1141.
2. Brodaty H, Draper B, Saab D. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: Prevalence and predictors. International Journal of Geriatric Psychiatry 2001; 16: 504-512.
3. Snowdon J. A follow-up survey of psychotropic drug use in Sydney nursing homes. Medical Journal of Australia 1999; 170: 299-301.
4. Bronskill SE, Anderson GM, Sykora K etal. Neuroleptic drug therapy in older adults newly admitted to nursing homes: Incidence, dose and specialist contact. Journal of the American Geriatric Society 2004; 52: 749-755.
5. De Deyn PP, Carrasco MM, Deberdt W etal. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioural disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 2004; 19: 115-126.
6. Deberdt WG, Dysken MW, Rappaport SA etal. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. American Journal of Geriatric Psychiatry 2005; 13: 722-730.
7. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. Journal of the American Medical Association 2005; 293: 596-608.
8. Jeste DV, Okamoto A, Napolitano J, Kane J, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. American Journal of Psychiatry 2000; 157: 1150-1155.
9. Lieberman JA, Tollefson G, Tohen M, Green AI. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomised, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003; 160: 1396-1402.
10. Wooltorton E. Risperidone (risperdal): Increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal 2002; 167: 1269-1270.
11. Schneider LS, Dagerman KS, Inse P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005; 294: 1934-1943.
12. Committee on Safety in Medicines. Atypical antipsychotic drugs and stroke 2004. [cited 21 November 2005]. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/ con019488.pdf
13. Schneider LS, Tariot PN, Lyketsos CG etal. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimers disease trial methodology. American Journal of Geri Psychiatry 2001; 9: 340-360.
14. Gill SS, Rochon PA, Herrmann N etal. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. British Medical Journal 2005; 330: 445.
15. Wang PS, Schneeweiss S, Avorn J etal. Risk of death in elderly users of conventional versus atypical antipsychotic medications. New England Journal of Medicine 2005; 353: 2335-2341.
16. Liperoti R, Gambassi G, Lapane KL etal. Conventional and atypical antipsychotics and the risk of hospitalisation for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine 2005; 165: 696-701.
17. Nasrallah HA, White T, Nasrallah A. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. American Journal of Geriatric Psychiatry 2004; 12: 437-439.
18. Brodaty H, Ames D, Snowdon J etal. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry 2003; 64: 134-143.
19. Cavazzoni P, Young C, Polzer J etal. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. NCDEU 2004. Indianapolis, IN: Eli Lilly, 2004.
20. Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: Comparison with QT interval prolongation for assessment of risk of Torsades de Pointes. Journal of Clinical Pharmacology 2001; 42: 577-579.
21. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Annals of International Medicine 2001; 135: 32-40.
22. Ray WA. Evaluating medication effects outside of clinical trials: New user design. American Journal of Epidemiology 2003; 158: 915-920.
23. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
24. Ray WA. Observational studies of drug and mortality. New England Journal of Medicine 2005; 353: 2319-2321.
25. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry 2004; 161: 1113-1115.
26. Ray WA, Meredith S, Thapa PB, Meador KG. Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 2001; 58: 1161-1168.
27. Report of the Working Party of the Royal College of Psychiatrists' Psychopharmacology Sub-Group. The association between antipsychotic drugs and sudden death. London: Royal College of Psychiatrists, 1997.